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“We are not paid—they just give us”: 
Liberalisation and the longing for  
biopolitical discipline around an   
African HIV prevention trial
P. Wenzel Geissler1
INTRODUCTION
The end of the monolithic biopolitical collective
From the vantage point of the mid-20th century, it seemed as if an almost 
inevitable connection existed between ideas and practices shaping the well-being 
of people’s bodies, and the larger body of the national collective, represented by 
its government. The somatic existence of citizens and the larger form of the 
nation-state jointly demarcated biopolitical space, our later understandings 
of which were shaped, among others, by Michel Foucault’s early writings on 
scientiﬁc knowledge and the clinic. The nature and operation of the nexus 
between medicine and nation was then open for discussion—ranging from the 
critical scrutiny by Foucault (but also e.g. Illich 1976), to the positive appreciation 
of national health as a collective political programme, epitomised in the works 
of Richard Titmuss (1970). Yet, that such a nexus existed, and that our thinking 
about the biological as well as the political had to take place within the remit of 
the national collective, was not put in serious doubt before the end of the 20th 
1 | I gratefully acknowledge the assistance of the scientists, research staff, clinicians 
and participants of the Kisumu HIV trials. Warm thanks to all present and past colleagues 
in the ‘Research communities study’, notably Philister Adhiambo Madiega and Gemma 
Jones, as well as to research students Patricia Kingori and Tracey Chantler. Ruth Prince 
and Ann Kelly offered invaluable advice on earlier versions. Particular thanks, to the 
senior colleagues from KEMRI and CDC, who allowed us to study their work. Fieldwork 
was funded by the Wellcome Trust with support from the Max Planck Institute for Social 
Anthropology (Research group ‘Law, Organisation, Science and Technology’). 
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century. One of the premises of this volume is that this has changed, that the 
once taken for granted bond between individual and collective body, citizen and 
nation, has been ruptured, or at least that it no longer is the dominant frame of 
biopolitics.
The dissolution of the uniﬁed collective, the nation, as frame of biopolitical 
intervention is hard to overlook in Africa. Outside South Africa, national academic 
institutions have ceased to produce recognised medical science and have passed 
on this task to “para-statal” institutions that adhere to neoliberal regimes of 
ownership, property and global standards, and operate largely dependent upon 
funding, expertise and organizational structures in Europe or North America. 
Biomedical health care provision is no longer procured, nor indeed often 
expected, from the state, but provided on a fragmented, partial, emergency-
focused basis—as ‘projects’ and ‘interventions’—by non-governmental and 
transnational agencies and programmes. For the inhabitants of mutating 
African nation-states, the demise of the national biopolitical collective implies a 
progressive ‘baring of life’; no longer anchored in the entitlements and duties of 
citizenship in its older nation-state sense, they have to orient themselves within 
less coherent geographies of rights and responsibilities. 
Crucial for those living under these conditions is the search for association, 
not only to others who in similar conditions pursue aligned interests, or to 
those in more privileged positions through whom resources or power can be 
accessed, but to larger wholes that, while never replacing the comprehensive 
imagined community of the nation, partially substitute it or patch some of 
the holes in its strained texture. Ethnographic observations of this quest for 
association have over recent years produced a plethora of (always partial, often 
‘biological’, somatically grounded) ‘citizenshipS’, with the plural referencing a 
qualitative shift away from the older totalizing notion of citizenship rooted in 
enlightenment readings of classic civitas. This inﬂationary use risks abrogating 
the claim for citizenship as comprehensive emancipatory reference to (just) 
society; but notwithstanding whether one calls any quest for collectivization a 
citizenship or not, this searching movement for larger associational forms is 
very important for contemporary African lives. It may be expressed in shifting 
religious groupings that have been observed in cities across Africa for several 
decades, through attachment to development projects or NGOs, to single-
disease vertical treatment programmes or, as I will suggest further on in this 
essay, through participation in medical experiments.
Transnational clinical trials and post-nation-state biopolitics 
Social scientists have observed, over the past decades, a proliferation of 
transnational medical research—especially clinical trials conducted with 
funding and expertise residing in institutions in Europe and North America, 
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upon bodies, and in collaboration with medical institutions, in post-socialist 
and postcolonial nations (e.g. Petryna 2002; Rajan 2006; Cooper 2008; 
Reubi 2010; see also Turnbull 2003, Leach/Fairhead 2007). These trials diﬀer 
(to some extent) from clinical trials conducted in the same countries where 
pharmaceutical industry and leading scientiﬁc institutions reside, because they 
stretch across vast inequalities in health and resources.2 And they are diﬀerent 
from clinical trials conducted within the framework of national health services 
in that they involve non-nation actors and thereby create diﬀerent bioscientiﬁc 
territorialities. The most prominent publications about this new regime of 
clinical research concern south-east Asia and the territories of the former Soviet 
Union: these areas diﬀer from Africa in terms of their relatively well-organised 
health and scientiﬁc infrastructure and their highly trained, but comparatively 
cheap, scientiﬁc work force, as well as in their disease patterns (resembling 
those of major Euro-American drug markets), which has made them a main 
target for pharmaceutical companies’ drug trials.
In Africa outside South Africa, this type of for-proﬁt transnational research 
is still relatively rare although it is likely to grow, for example in relation to 
anti-cancer treatment (see Livingstone 2012). The dominant transnational 
formation of bioscientiﬁc production in 21st century Africa is not the corporate 
pharmaceutical drug trial, but the publicly funded collaborative ﬁeld station 
or research centre, often with an associated demographic surveillance system, 
sizable areas, often with several hundred thousand inhabitants, where 
demographic events as well as morbidity are closely surveyed, in view of 
providing a sampling frame for controlled clinical trials of health interventions 
and vaccines (see e.g. Adazu et al. 2005). Such ﬁeld stations—involving large 
‘Northern’ scientiﬁc organisations such as the USA’s Centres for Disease 
Control, the British Wellcome Trust and Medical Research Council, and some 
of wealthy American universities, in conjunction with African para-statal 
organisations or health facilities—have over the past three decades emerged 
all over Africa. Disposing over highly trained and motivated scientiﬁc leaders, 
state of the art laboratories, large and highly trained, ﬂexible workforces, and 
the mentioned highly capital intensive demographic surveillance systems, these 
ﬁeld stations have become the primary sites of bioscientiﬁc production on the 
African continent, and have largely replaced African academic institutions as 
well as national ministries of health, with whom they sometimes collaborate, as 
centres of scientiﬁc productivity and excellence.
2 | While this dimension of inequality is absent in the remaining strong nation and 
welfare states (e.g. Scandinavia), where most trial participants are recruited from the 
general pupulation, clinical trials in less egalitarian western societies such as the USA 
do of course share many of the ethical and political challenges of transnational clinical 
trials (see e.g. Abadie 2010).
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These new large-scale units are exemplary of the biopolitical forms of 
the post-neoliberal age in Africa. Their relationship to the nation-state is 
weakened, even though the African partner organisations are often ‘para-statal’ 
organisations combining state endorsement with corporate traits, and although 
they continue to rely on state regulation and state health facilities for subject 
recruitment and above all for post-trial referral. Usually they are situated close 
to participant recruitment areas—hence the term ﬁeld station—and distant from 
centres of national government or higher education, as well as from the global 
‘centres of excellence’ to which they are attached. Due to the high capital input 
in a context of generalised poverty, these installations tend to be segregated from 
the surrounding territories—creating enclaves of perfect bioscientiﬁc possibility 
within the wastelands of post-nation-state health care and academia. Biomedical 
science, rather than progressively extending its reach over a national territory, 
contracts here into islands; the possibilities and aspirations of the modern 
rendered as an archipelago. Connections to the national loci of public health 
governance are sometimes challenging, while worldwide communications, 
material ﬂows and data exchanges among such enclaves of global bioscience, 
and between them and the mother institutions in the North are immediate—
‘hopping’ as it were in real time across the globe.3 As such, the geography of 
contemporary African clinical trial sites reﬂects the novel territoriality that 
anthropologists have described for neoliberalised African resource extraction 
industries—e.g. multinational mining corporations’ and oil industries’ ‘capital 
hopping’ and ‘enclaving’ (see Ferguson 2006). They do thus have a distinctly 
‘neoliberal’ ﬂavour to them, without, however, the direct economic causalities, 
which shape pharmaceutical companies’ drug trials.
A second characteristic trait of these installations, intertwined with their 
spatiality, is their experimental temporality. Their activities are, unlike those 
of state education or national health care, never explicitly long-term, although, 
incidentally, many of these sites look back at 20 or 30 years of existence. Instead, 
they are framed by time-limited funding cycles and temporary contracts, and 
3 | Characteristic of these real-time global data neworks are disease specific 
consortia, such as the HIV Prevention Trials Network (www.hptn.org) or the Malaria 
Vaccine Initiative (www.malariavaccine.org), which produce ‘multi-site’ trials, which 
are centered in some global centre of academic excellence, and recruit participants 
(often competitively, racing against time) in sites accross the globe, continuously 
pooling data from study subjects in dif ferent parts of the world; many of the most 
infkuential and important medical research endeavours of our time are organised in 
this way. Another example of a global network of scientific spots is the International 
Network for the Demographic Evaluation of Populations and Their Health in Developing 
Countries (INDEPTH) (www.indepth-network.org), which links health and demographic 
surveillance areas from around the globe.
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by the limited horizons of experimentation, which extend towards previously 
deﬁned endpoints in time—‘outcomes’. With this experimental mode of 
engagement between research institutions and their congregation comes a 
particular relationship between knowledge and action, in which interventions 
(treatment, disease prevention) are conducted as experiments, without certainty 
about the outcomes; although such ‘experimentality’ could be said to have 
existed in earlier, colonial, scientiﬁc regimes (e.g. Lachenal, this volume), it 
becomes a dominant trait of present scientiﬁc work in Africa, partly because of 
the retreat of long-term state interventions based on consolidated evidence (see 
Rottenburg 2009). Again, these temporal and epistemological conditions are 
not limited to the production of scientiﬁc knowledge, but resemble the politics of 
‘exception’ that anthropologists have described as foundational to contemporary 
formations of global capitalism (e.g. Ong 2006), without, however implying the 
same economic determination.
As far as the economics of contemporary African trial sites are concerned, 
much funding still originates from national governments—albeit not the 
governments of the nation’s where these stations are situated, but that of 
Northern nations government budgets—and not from private corporations. 
There is a signiﬁcant and growing proportion of ‘public private partnerships’ in 
which private funding, including that of pharmaceutical industry contributes, 
and shapes, public scientiﬁc enquiry (see Gerrets this volume), but the dominant 
source of funding remain national government institutions like the US NIH, or 
the UK MRC, and public charities like the Wellcome Trust. Despite the overall 
public nature of these institutions, by contrast with the commercial clinical 
trial settings described for Eastern Europe and south-east Asia, the way these 
installations are managed and audited, the ﬂexible short-term contracts under 
which the (predominantly) local workforce is employed, and the structures 
of transnational management and funding ﬂows, is not entirely dissimilar 
to transnational corporations. Control over the scientiﬁc production process 
resides with Northern institutions, data is often transferred to and analysed by 
these, and published by British and American academic journals; processes are 
managed and supervised by these institutions and their staﬀ, and the existence 
and continuity of the institutional arrangement depends upon them.
Similar debates about the production and distribution of value created 
by scientiﬁc labour that apply to multinational corporations’ outsourced 
production sites in post-colonial territories, arise then from today’s African ﬁeld 
stations, although the value produced and transacted around these sites is less 
directly identiﬁable as a form of capital. Economic questions about exploitation, 
accumulation and justice are here often negotiated through the idiom of research 
‘ethics’, which—if sometimes by implicit evasion or explicit exclusion from its 
purview—engages economic contradictions in the idiom of justice, freedom 
and social good. It is the active exclusion of value from view that such ethical 
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reﬂections and regulations often encourage, that provide my starting point for 
the discussion about experimental value and collective below.
The ethics and politics of bioscientific value
Bioscientiﬁc value has recently received attention from anthropologists and 
bioethicists who—from diﬀerent institutional and political viewpoints—
emphasise the political, economic and practical challenge that this value poses, 
at this particular juncture, and in economically deprived regions (for ethicists 
see e.g. Dickert/Grady 1999; Lemmens/Elliott 1999; Anderson/Weijer 2002; 
for anthropologists see Petryna 2005; Rajan 2006; Hayden 2007; Cooper 2008). 
The discussion includes very diﬀerent viewpoints: traditional bioethicists who 
insist on the ‘social value’ of scientiﬁc knowledge and reject consideration of 
individual interests and proﬁt, those who propose value-distribution through 
‘beneﬁt sharing’, others who denounce the privatised value of pharmaceutical 
research and uphold the virtues of the nation-state, and ﬁnally those who propose 
to resolve matters by re-evaluating research participation as paid ‘clinical labour’.
What is at stake in all these approaches to the problem of value arising from 
scientiﬁc production under conditions of economic inequality, is the relation 
between value and collectives (or processes of collectivisation); who creates 
the value; who is the rightful owner of this value—society, mankind, nation, 
individuals, or other, intermediate collectives; and how, by whom, and to whom 
should value be transferred? Value is produced, and disbursed, within and 
among collectives; but what these collectives are has become much less clear 
today, compared to when medical science was produced by state institutions 
through the scientiﬁc and bodily labour of national citizens (see Hayden 2007).
This chapter contributes to this discussion about value and collectives, and 
to the wider problem of post-governmental biopolitics in Africa, by examining 
the practice of ‘transport reimbursement’—small ﬁnancial payments to trial 
participants on the occasion of their participation in clinical or data collection 
procedures. These are part of most medical research settings; I will here 
discuss them in relation to HIV research conducted in Kisumu, Kenya, in 
collaborations between KEMRI and its main overseas collaborator, CDC.4 I draw 
upon interviews, conversations and observations with research participants and 
4 | KEMRI was founded by government act in 1979, as one of several ‘para-statal’, 
usually collaboratively funded, scientific institutions. The US government CDC is a 
main collaborator, conducting research on malaria, HIV and emergent diseases. KEMRI 
and CDC have since 1979 focused on western Kenya and have jointly built the KEMRI/
CDC field research station, which is part of the KEMRI ‘Centre for Global Health’ which 
has expanded continuously during the 1990s and is today one of the leading medical 
research sites in Africa, with world-class laboratories and an annual budget in excess of 
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staﬀ during long-term ethnographic ﬁeldwork among the ‘trial community’ 
(Geissler/Molyneux 2010) of a scientiﬁc study evaluating an innovative regime 
of maternal triple anti-retroviral prophylaxis from late pregnancy through six 
months of breastfeeding for the prevention of mother-to-child transmission of 
HIV (PMTCT).5 The study showed that the relatively inexpensive experimental 
regime could reduce mother-to-child HIV transmission to less than one ﬁfth of 
the rate that one would have expected under standard medical procedures in the 
area; indeed, the rate of transmission at birth was only little higher than what 
would be the case in developed country medical settings (Thomas et al. 2008). 
The trial lasted from 2003 to 2009, and involved over 500 women, who were 
recruited from antenatal care centres upon their diagnosis as HIV positive. The 
women and their babies were followed for up to two years after delivery. Most of 
them lived at the beginning of the study in the city of Kisumu, but many moved 
during the follow-up between city and rural areas, reﬂecting the instability of 
many young women’s lives in Western Kenya today (see e.g. Geissler/Prince 
2010). In spite of the practical diﬃculties arising from this mobility, the trial 
lost few participants, because the women, for various reasons, liked to be part 
of it—which, as I will discuss below, is very important for our understanding of 
the value of scientiﬁc work, and the collectives it engenders. 
In this essay, I will show, ﬁrst, that the ﬁnancial transactions called ‘transport 
reimbursement’ are generally understood not as reimbursement—i.e. zero-
sum transactions—but as net value transfers, and that all members of the ‘trial 
community’—study participants and the people they live among, research staﬀ, 
and scientists—are aware of this discrepancy between the nature of the payments 
and the term by which they are referred to. The term ‘transport reimbursement’ 
attempts to render invisible the value of these transactions, responding to 
regulatory objections to payments or what bioethicists refer to as ‘undue 
inducement’, and as a result, it removes the problem of value from the sphere of 
legitimate discourse. Speaking about this un-spoken materiality aﬀords us then 
an opportunity to prise open the transactions of value in transnational clinical 
trials in order to rethink the political project of public health science, beyond 
the alternatives of ethics and market, gift and exchange, that shape much of the 
on-going bioethics debate, especially in Kenya. This will lead us to reﬂect about 
the potential collectives and aspired-to futures—emergent ‘citizenship(s)’ (see 
Whyte 2009) or the ‘publics’ in public health—which are referred to as well as 
USD30 million, hosting approximately 1,500 staff members, funded by CDC and other 
funders, and employed by KEMRI, and hundred thousands of participants. 
5 | Fieldwork was conducted from 2006 to 2010 with the approval of KEMRI, CDC and 
other collaborators involved in HIV research. I am grateful for the support and trust we 
received from our colleagues. This ar ticle presents the author‘s reflections and aims to 
contribute to an open discussion with scientists and ethicists. 
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produced by clinical trial engagements. Thus the discussion returns us to the 
political promise and responsibility of public health, as in producing health and 
engendering a collective.
TR ANSPORT REIMBURSEMENT 
“So what shall I call this?”
Every Friday morning the coordinator of one of the HIV trials conducted in 
Kisumu, Kenya, meets his staﬀ, including clinicians, laboratory technicians, 
counsellors and interviewers, employed by the Kenyan Medical Research 
Institute (KEMRI) in collaboration with the Centres for Disease Control and 
Prevention (CDC). On this day, about 20 staﬀ members are gathered in the 
conference room of the custom-built clinical research centre. The principal 
investigator (PI), who usually attends staﬀ meetings, is absent. One purpose 
of the meeting is to discuss encounters with speciﬁc trial participants. A 
clinician reports about a pregnant participant who asked for transport to the 
clinic because she felt unwell and could not walk. After she was taken to the 
clinic by taxi, she asked for ‘transport reimbursement’, which she regarded as an 
entitlement. When the clinician told her that she could only have the taxi fare or 
reimbursement, she responded that she would then come on foot anyway. The 
case provokes lively discussion, in which the majority of staﬀ members advocate 
to pay both for the taxi and for transport reimbursement.
When the clinician concludes: “She was not really sick. She could walk ...”, a 
female ﬁeld staﬀ objects: “You can’t do this. She is pregnant, she maybe cannot 
walk! Do you still want her to walk all the way in order to get the reimbursement?” 
Another male clinician interjects: “We have to look at the ethics. We should not 
be seen as coercive, and we must not set a precedent.” The female colleague 
retorts: “Now who will see this?” Patiently, the second clinician continues: 
“Transport reimbursement is supposed to take care of her transport. Now if 
you give her taxi [ fare] and then you still pay her transport reimbursement, this 
is transport to where? If I still pay her, what shall I then call this?” “Transport 
reimbursement!!” retorts the female staﬀ, supported by laughter and nodding 
from other staﬀ members. The clinician pauses and resigns, proposing to 
take the matter up with “the powers that be”, the PI. Everybody including the 
clinicians laughs. No further action is taken on the matter.
On this rare occasion, the problem of ‘transport reimbursement’ was made 
explicit, for a moment, before being covered again by terminological rigour 
combined with mirth and irony. For a moment the gap between names and 
things was opened, but it was quickly closed again, quite rightly so, because 
nobody present, nor the “powers that be” can resolve it. I do not want simply 
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to denounce this discrepancy between rules and realities, but take it as a point 
of departure to reﬂect about transactions of value in clinical research in HIV 
trials in Africa. The rhetorical question posed in this exchange: “transport to 
where?” orientates my enquiry, as I will suggest that one important function of 
value transfers like transport reimbursement, pharmaceutical treatment, blood 
specimens or clinical data, intertwined with the more immediate fulﬁlment 
of vital needs, is to propose emergent collectives, to evoke futures, engender 
movement and seek direction—indeed transport towards better lives. 
“We don’t pay…” 
Practices and discussions as well as silences around ‘transport reimbursement’ 
(TR) concretise the problem of value, faced by transnational research in the 
current historical and political-economic moment.6 TR is one of many transfers 
of material value to individual study participants, which, in the Kenyan context, 
may include medical treatment and pharmaceuticals, food, bars of soap, bed 
nets and water containers and other health enhancing commodities.7 TR 
is distinguished from these by being monetary, which makes it particularly 
problematic to bioethicists sharing a broadly ‘western’ understanding of money 
as abstract, calculative and individuating (see e.g. Maurer 2006). A bar of soap, 
a cinema ticket or a project party can here more easily be construed as a gift 
because none of them is vitally necessary, and the ﬁrst has additional legitimacy 
because of its health impact. Such gifts are often referred to in the trial context as 
‘a thank you’, rather than as an ‘incentive’. By contrast (general purpose) money 
is, in this tradition, not suitable as a gift or ‘thank you’ because it is convertible 
and invites calculation and notions of economic exchange.
The aversion to money changing hands within a public health context 
extends—at least in the eyes of many older public health experts—to the 
wider health care services. Only after considerable national and international 
scholarly debates could so-called “user fees” for government health services be 
introduced within the broader framework of neoliberal “structural adjustment”; 
today, Kenyans have to pay contributions to almost all medical services provided 
by government facilities; and although these fees are relatively low, they do set 
6 | Since in most economically deprived settings, receipts for transport are hard to get 
(or all too easy to obtain), TR is often based on fixed rates specific to a site or a particular 
trial. Rates vary between collaborative sites and sometimes between research groups 
and projects in one site, usually ranging from 2-5£ (higher amounts being paid in trials 
based at referral hospitals covering large areas, and for participants who for various 
reasons travel long distance).
7 | Even cinema tickets, underlining the attempts to retain the notion of the gif t and the 
effor t to keep transactions separate from any actual needs and survival.
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limits to the care available to poorer people, they opened, some argue, the door 
to inoﬃcial payments and corruption in health facilities, and they did away with 
the idea of health care as a service that the nation bestowed upon its citizens (see 
e.g. Mwabu et al. 1995). It is this liberalised world of illness and health, which 
provides the context for local understandings of value transactions in clinical 
research.
As money may easily be confused with ‘payment’, regulatory ethics 
guidelines applied in Kenya insist that monetary transactions should be a mere 
prevention of cost;8 the sum of transport fare and reimbursement is assumed to 
be zero; no personal gain should be incurred. 
Like in most transnational research sites in Africa that adhere to ‘Good 
Clinical Practice’ (GCP) and international ethics guidelines, net monetary 
beneﬁts for participants—‘incentives’ or even ‘payments’—would here be 
considered ‘undue inducement’ contrary to the spirit of voluntariness, and 
they would not be given approval by the Institutional Review Boards (IRB) that 
assess project ethics. Likewise, IRB approval can be denied if the proposed TR, 
which increasingly has to be speciﬁed on the research protocol and information 
materials and consent forms, is considered too high, constituting ‘coercion’ of 
poor participants. Oﬃcial documents emphasise therefore the link between 
reimbursement and travel, relating reimbursement rates either to transport 
fares or to distance, but not usually to other equivalents such as time spent, eﬀort 
undertaken, leave alone risk incurred. In accordance with these conventions and 
with written study documents, if TR is discussed among trial staﬀ and especially 
with participants, any mentioning of ‘payment’, as in ‘how much do you pay 
your participants?’ is likely to be rebuked by a ‘we don’t pay’. 
Reimbursement and voluntarism are ﬂip sides of one coin: the notion 
of reimbursement safeguards the freedom of voluntariness, in the sense 
of individual choice. The signiﬁcance of using ‘reimbursement’ instead of 
‘payment’ is underlined in the terminology applied to another kind of bodily 
research participation in entomological research conducted by KEMRI around 
Kisumu: young men recruited to catch mosquitoes oﬀ their bodies (human 
landing catch), and those who sleep in tent-traps to catch mosquitoes, can only 
be recruited as ‘volunteers’ and be given ‘reimbursement’ for that time as well as 
the risk of malaria infection (reduced by chemoprophylaxis); their remuneration 
must not be referred to as ‘payment’, and rather than employment contracts, 
they sign consent forms. By contrast, young men recruited from the same 
village communities to set mosquito traps or empty them are employed as casual 
8 | In other regularly contexts (e.g. USA) payments are acceptable, even to pull 
participants, as long as they do not induce unreasonable risk taking (undue inducement), 
but even where such payments are formally allowed, they often draw public moral 
debate, such as around the 2006 British Parexel incident (e.g. Wadman 2006).
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workers and paid exactly the same amount as volunteers for a speciﬁed number 
of hours. The terminological rigour is important here, so as not to create the 
ethically problematic situation in which one pays for bodily risk. Lending one’s 
body to science remains here linked to voluntarism and citizenship, to avoid the 
potential accusation of exploitation, which does not seem to arise from ordinary 
labour relations. Apart from terms, however, the two kinds of research work and 
pay are identical.
To maintain the moral value of autonomy, and to protect participants 
from the force of resource-rich research institutions, transfers of material 
value, notably money, to them are avoided or kept minimal. While this is the 
argument behind ethics rejections of ‘inducement’, one could argue that the 
notion of ‘voluntariness’, understood as autonomous choice without material 
entanglements, is anyway less than straightforward under conditions of extreme 
poverty—in the words of one scientist ‘a bit of a middle/upper class luxury’—and 
that one should instead explore concepts such as ‘responsibility’ or, in medical 
terms ‘care’, as a frame for ethical scientiﬁc engagement. I will return to this.
Reimbursement in western Kenya
TR is a relatively recent development. When I conducted epidemiological 
research in Western Kenya in the early 90s, study participants in rural areas 
did not expect monetary transactions around their research participation. 
Indeed, the government scientists and technologists with whom I worked at 
the time where strongly opposed to the idea, both on the grounds that they 
regarded people’s participation in research as a citizen’s duty (reciprocated by 
their own eﬀorts at government disease control), and because they feared that 
independent research by Kenyan government agencies without external funding 
would be made impossible if Kenyan citizens would expect individual payments 
for blood, stool or urine specimen delivery. In other words, at the time the 
collective nation-state frame of medical research and public health intervention 
was still taken for granted; from this followed not only that participants were 
not paid, but also that their consent, as citizens, was taken largely for granted 
by the government researchers, and no individual written consent was sought.9 
9 | The organisation that I worked with at the time, and which had dominated medical 
field research in Kenya for many decades, was probably relatively more conservative 
in its civic values and ‘developmentalist’ nation-state imaginary than others who 
began operating in the area at the time, and who eventually took over at the helm of 
medical research. The anachronism of some of their procedures in a changed scientific 
world, in which good science was no longer nation-state public health, but ‘Good 
Clinical Practice’, became very clear when a large collaborative project of the former 
(government) organisation was closed down in 2000 after an external review by North 
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Since that time, new agencies have become leading in Kenyan medical research, 
and the social contract that the older generation then still envisioned as basis 
of public health science has been eroded; instead, along with standard consent 
procedures, TR has become an obligatory part of medical research and potential 
research participants are keenly aware that research participation entails some 
monetary transactions. 
Among the reasons for transport reimbursement becoming ubiquitous in 
Western Kenya are changes in the conduct of transnational medical research, 
its relation to the national health system, and the wider political economy, from 
epidemiological ﬁeld research to the model of clinical trials run according to 
global regulatory frameworks—and the attendant transnational transfer of 
procedures and models, as well as growing prominence of Euro-American 
institutions in research collaborations. While up to the early 1990s collaborative 
medical research projects in Kenya had minimal expatriate staﬀ and operated 
usually within facilities provided by the Ministry of Health, using government 
transport and permanently employed civil servant staﬀ, today’s medical research 
programmes in Western Kenya are widely known by the name of their overseas 
collaborative partners, and recognised by their custom built research centres 
and laboratories (often erected within or next to public facilities but recognisably 
diﬀerent from them) and their highly visible modern transport ﬂeet. Staﬀ—
on temporary short term contracts funded by the external collaborator—and 
research participants today tend to identify with the overseas collaborator (as in 
‘I’m with ...’) rather than with national government and citizenship.
While medical research in the past used to be integrated more tightly with 
government health care provision and often directly linked to public health 
campaigns, the social beneﬁt of today’s transnational clinical trials is often 
less immediate and visible to participants—mediated through a long loop via 
academic centres of excellence in the USA, and international policy bodies 
such as WHO, making short-term beneﬁts a more salient and contested 
issue. Moreover, the exponential growth of medical research and aid activities 
in Western Kenya—one of Africa’s key HIV intervention zones—has during 
the last decade led to a very diﬀerent local economy, marked by new income 
opportunities and raised expectations of monetary gain among the general 
populations (see also Prince, this volume). In areas like this, models and 
relationships derived from medical research have extended across society, and 
transport reimbursement—tied to the notion of ‘voluntary’ action—has gained 
currency far beyond the limited purview of medical research. Thus, in HIV care 
and treatment, which in this area are again spearheaded by KEMRI and CDC, 
American reviewers, who found the ethics procedures lacking. This was, then, the 
definite endpoint, in Kenya, of medical research premised on and legitimesed by the 
taken for granted social contract between citizen and nation.
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large numbers of ‘volunteers’ assist donor funded patient support centres with 
recruiting, counselling and testing, and tracing patients who defaulted, as peer 
educators and by transporting blood samples and managing patient records. 
Volunteers may in such facilities well outnumber regular employees, and the 
status of the volunteer—often envisaged as a step between HIV self-help or 
‘peer’ assistance, and more formal employment in the HIV-NGO sector—has 
become emblematic of especially younger people’s lives in Western Kenya. 
As volunteers, they are not paid for their labour, but given ‘reimbursement’ 
or ‘tokens’. This economy of voluntarism and reimbursement opens up new 
possibilities of engagement, learning and civic identity to young people, but it 
also creates possibilities of exploitation and abuse by institutions and by formally 
employed actors. 
Do we have a Standard Operating Procedure? 
The fact that transport reimbursement still is a relatively new phenomenon is 
reﬂected in the ﬂexibility of the practices around it. Thus, in the HIV prevention 
trial we followed, the project protocol from 2003 contains no details about TR. 
The fact sheet for prospective participants states under “beneﬁts” that: “Neither 
you nor your baby will be paid for being in this study. But you will receive money 
to pay for your transport,” and, under the heading of “costs”, that: “there is no 
cost to you or your baby for the study drugs, study clinic visits, physical exams, 
transport to study clinic visits, lab tests for the study, or for your delivery at 
the hospital.” An attached sub-study protocol speciﬁes: “Participants will be 
reimbursed transport according to standard ... guidelines already described in 
the main study protocol. For their time, sub-study participants, like all KEMRI/
CDC participants will receive a bar of soap.” The main protocol does not specify 
amounts, presumably based on the assumption that actual transport expenses 
will be refunded. The distinction made here between monetary reimbursement 
and soap as appreciation of time underscores the careful hedging of monetary 
transfers as presumed zero sum transactions, separate from gifts and not to be 
confused with exchanges. 
When the PI, after the end of the study, tried to ﬁnd us some documentation 
of reimbursement rules and asked his staﬀ for the ‘standard operating 
procedure’ (SOP), no such document existed, although trial practices had been 
regulated in great detail by speciﬁc SOP’s. The staﬀ member who had been 
in charge of reimbursements explained retrospectively: “We did not have an 
SOP for transport reimbursement. The initial ﬁgure of 100 KSh was arrived 
at from [a preceding] study [in the same site]. After a while due to the amount 
of time mothers spent in the clinic it was agreed that we increase the ﬁgure 
by 200 KSh to compensate for the time they took in the clinic” (K29; e-mail, 
May 4th 2010). This change of rates, motivated partly be the realisation that 
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some women travelled longer distances, and partly by the long time the study 
procedures took, was recorded in staﬀ meeting minutes, which were the only 
oﬃcial written document concerning TR rates for this study: “scheduled visits 
participants will receive Ksh.300 [up] from Ksh.100” and, “participants will start 
receiving Ksh.300 on enrolment” (Minutes K, August 2006). These decisions 
were taken by research staﬀ and the PI based on practical experience and 
personal judgement, joint deliberation and improvisation in a setting where 
even the most mundane research procedures were ﬁxed in written SOPs. Part 
of the motivation behind the threefold increase of the rate was to provide some 
payment over and above the actual transport fare (which at the time was about 
50 KSh for most distances within Kisumu), as underlined by the provision, in 
the same minutes, that for “those who come from far Ksh.200 will be added on 
the rates they receive.” Moreover, the additional 200 shillings were only to be 
paid for visits to the clinic relevant to the study, whereas “unscheduled visits” 
due to sickness were only compensated by the old rate of 100 shillings, based 
on the assumption that those who attend the clinic for health reasons already 
receive a beneﬁt and do not need further incentive. As the PI recalled: “There 
was quite a bit of abuse going on with sick visits... we ﬁgured we were already 
providing care for the sick visit, so perhaps we could compensate a little bit less 
for transport” (C26.3).
Between 2003 and 2009, transport reimbursements were regularly paid 
to over 500 participants. The amount paid was based on the considerations 
discussed by the study team, which were not recorded as they arose in everyday 
practice. The PI recalled the discussions with study staﬀ: 
“Well, ...it is fair to say for someone who walked, it covered more than their transport, 
literally their transport reimbursement. […], there was another rationale there ... we 
were setting it perhaps at the minimum wage? Which was about 250, so we were slightly 
above minimum wage. I think just to compensate…they may be there for a long time, 
so ...they might have been, could have been, working, ... to compensate. And we did, 
for women who came a long way and brought a receipt, we compensated even over and 
above [the actual rate].” (C26.3). 
This PI was particularly thoughtful and open about his considerations, and the 
potential ethical issues involved—“I mean its a ﬁne balance, you know, to sort of 
compensate people for their time, sitting in a matatu [minibus]… without being 
coercive.” (C26.3)—and he repeatedly encouraged us to study TR, which he, like 
other colleagues, found a slightly awkward concept. Similar themes emerged in 
conversation with other PI’s and study coordinators, who were struggling with 
the task of setting an adequate rate, aware of ethical norms of non-payment 
as well as participants’ needs and the requirements of trial management. 
Some said they had used an assumed minimum wage as a standard, others 
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had added a token onto documented transport fees, others again had copied 
other research groups. Underneath the seeming obviousness of the concept 
of ‘reimbursement’ many other considerations were at play and informally 
negotiated. These included questions of justice and ethics, and personal 
commitment to provide some help for poor study subjects, but also budgetary 
constraints, competition with other groups for participants, and concerns with 
recruitment rates and participant retention. The resulting negotiations between 
researchers and research staﬀ were somewhat improvised, and with little input 
from participants.
Stabilisation
At the time when our study came to an end, transport reimbursement became 
stabilised in an oﬃcial document. This was provoked by an oversight: a 
research student moving from the urban research zone to a rural area had 
used the common TR rate in the city (300 Kenyan shillings) on her ethics 
application for a new project in the rural area (reﬂecting growing awareness 
of the issue, by 2008 the KEMRI ethics committee required the stipulation 
of transport reimbursement rates in every protocol). Upon arrival on the new 
research site she realised that the rural rate was lower (120 Kenyan shillings), 
and other researchers on site understandably urged her to adjust her rate in 
order to avoid competition. When this change was submitted, with reference to 
‘standard guidelines’, as an amendment to the ethics committee, the committee 
comprehensibly wished to see those guidelines. In collaboration with senior 
colleagues, the research student produced oﬃcial ‘reimbursement guidelines’ 
which formally stated the diﬀerent rates for, respectively, the urban and the rural 
research site. It also ended ambiguities concerning the meaning of transport 
reimbursement—such as the reference to the time spent in the clinic, noted 
above—by stating: “Reimbursement is understood as meeting travel costs 
participants incur to attend study visits”, and specifying further that based on 
a “mapping exercise of rural districts” it had been determined “how much a 
participant would spend to travel to a facility” arriving at the lower rural rate, and 
that “travel costs are higher in peri-urban and urban Kisumu and participants 
usually travel longer distances to reach the research facilities” within the city, 
justifying the urban rate of 300 shillings.10
10 | Interestingly, the rural rate of 120 Kenyan shillings that had been determined 
through careful deliberations by the rural research teams prior to the formalisation of 
reimbursement rates, had, according to one rural study coordinator, been derived from 
comparison with approximate daily labour rates in agricultural production. While, as we 
saw above, the urban rates had been produced by adding 200 shillings—to appreciate 
time and effor t—onto an earlier rate inherited from a previous project, the rural rates 
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VALUE APPRECIATED, ACKNOWLEDGED AND HIDDEN AGAIN
Receiving reimbursements: ‘But I am paid’
Much as the notion of payment, and of monetary value, is avoided in oﬃcial 
trial documents, study participants perceive these transfers not as mere 
reimbursements. That they value the additional cash is unsurprising in a place 
where, for most people, a day’s manual labour would earn 100-200 KSh—
an amount that could pay for one substantial family meal—in a situation of 
generalised unemployment, rising food prices and unstable food production, 
where opportunities to earn even such modest amounts are scarce.
Participants expect, at least after some time in a project, reimbursement 
attached to every trial activity, usually even if they had no actual transport 
expenses or when a research team had come to visit them to collect data or 
conduct an interview. All participants expected some amount over and above 
their actual expenses—“they don’t give you the exact transport, you are just 
given, so it really helps.” (KP8)—and many were aware of the 200 shillings 
excess that had emerged from the deliberations above. The amount of cash that 
the participants took home varied slightly, depending upon the number of clinic 
visits and the actual transport expenses; but all mothers appreciated the money, 
and praised CDC’s ‘generosity’ (lit. ‘wide hand’, bade lach (KP18)), embodied by 
the PI, whom they referred to as the ‘owner/father of the clinic’ (wuon clinic) or 
the leader of the study (jatend [study]), and the attentive and generous KEMRI 
staﬀ. The idiom of generosity and the emphasis on the paternal ﬁgure inserts 
trial participation into a wider frame of patronage as local idiom of entitlement 
and responsibility. I will return to his relational and collectivising eﬀects of the 
payments below.
Even medical care and pharmaceuticals, probably the most important 
transfer of material value around trials and deﬁnitely more signiﬁcant than TR, 
was discussed by participants in monetary terms, when the prices of medical 
procedures such as deliveries, in public and private hospitals, were converted 
into costs. Several participants remarked upon the fact that the study not only 
liberated them of the cost of consultations and drugs—“Even if I’m a little sick, 
they give me good medicine which can cost a lot of money if I go to buy it 
and this relieves (lit. ‘frees’) me (giketa thuolo )” (KP8)—but even used “original 
drugs [brand packaged], not just drugs that are being sold ...” (KP 14). While 
these conversions of care into money underline the participants’ awareness of 
had been directly derived from comparison with labour rates. The result of the mapping 
exercise stabilised the more complex, contextualised considerations of research teams 
in city and rural area, and translated earlier deliberations about compensation for time 
and effor t into reimbursement for transport fees.
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value and the inseparability of value and care, their desire to be treated with 
‘original’ drugs also indicates, again, that there is more than money to these 
considerations. The care bestowed by the study is also associated with higher 
reliability, and with wider, more robust, global medical connections, for example 
to leading multinational pharmaceutical companies or the technical standards 
of ISO certiﬁed research laboratories: if one’s HIV test is done by the world’s 
largest and most inﬂuential public health agency, by staﬀ trained by a world 
leading old school of tropical medicine, or if one’s drugs are produced by a 
known multinational pharma-company and licensed by the FDA, one’s bodily 
state and well-being is, if ephemerally, connected to much larger wholes, 
which—despite the fears and concerns that power always also provokes in the 
powerless—engender expectations and trust that the nation-state health system 
can no longer instil in its citizens. Thus, while value calculations permeate 
social engagements of the trial, this does not prevent them from being linked to 
wider notions of belonging and care. I will come back to that.
Covering vital needs
The cash obtained through trial participation is quickly converted into 
life sustaining food—“something to swallow because, you know, we were 
breastfeeding, [...] so this money helped us a lot; we could have at least 
something to eat” (KP10). Invariably, the women describe how they would use the 
‘reimbursement’ for food, to eat, to obtain particularly “good food [such as fruit] 
to boost up your blood/foetus” (KP4), or, more commonly to feed their children 
and to share with others: “the money that we were given, these 200, was helping 
us all. When I leave Kisumu I carry something. Doesn’t it help everybody? You 
can buy something for the baby, and you can cook something in your house, 
and people share; so people are happy” (KP15). While daily food needs were 
the priority, some participants increased the value of their reimbursement by 
investing it, as they travelled between home and clinic: “the remaining fare [TR] 
made me join business; when I come to them I can go back with three or two 
pairs of shoes. I sell them higher than I bought them. The ones from this side 
have a bit of proﬁt” (KP15).
The small amounts of reimbursement money contributed to the women’s, 
and their children’s, lives in an economy of survival, where the means to satisfy 
one’s vital needs have to be found anew, day after day. Many of them described 
not having access to cash and often not knowing in the morning how to buy 
supper. Many lived in rented accommodation (single rooms) which cost around 
5-700 Kenyan shillings a month, and described a family meal as consisting of 
vegetables for 20 shillings cooked with tomatoes for 10 shillings, accompanied 
by maize porridge (in 2009, maize ﬂour cost 120 shillings for 2 kgs) which gives 
an indication of their regular cash ﬂows, that transport reimbursements added 
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to. The scarcity of money in these women’s lives, often controlled by husbands 
and relatives, was underlined by their quest for health care: “when the child 
becomes sick, or when I am sick, I am in problems. I don’t have money, I will 
not be treated. But then [with the study] I was just treated even if I don’t have 
money” (KP9). “Sometimes the baby is sick, you carry the baby for treatment; in 
the hospital you are prescribed expensive drugs but you cannot aﬀord them at 
that time, so you leave the baby until the sickness becomes worse, and only then 
you get money to go and buy” (KP18). 
Those who had moved out of the city since the beginning of the study to live 
with relatives experienced particular diﬃculties in obtaining even the money 
(at times less than hundred shillings) needed to take a child to hospital in town. 
They had to borrow from neighbours and relatives, promising them to repay 
upon their return—which, incidentally, was comparatively easy for those who 
were known to ‘be with KEMRI/CDC’, since the association made them more 
creditworthy; often they walked, even for hours. For poor HIV positive mothers, 
the possibility of reaching the city or a hospital is about survival: “If a child is 
sick or if I am sick, even when I am far, I can call them to come for me or I 
just go and they will pay the transport” (KP12). “[When I was told the study 
was over] I said ‘what am I going to do?’ I had got used to Kisumu: when I’m 
sick I just looked for fare to go to Kisumu, and they treated me, or my child” 
(KP15). To have an institution pay for your transport when the need arises—“If 
you really need to go, it is always easy to borrow from a neighbour, because in 
the evening, he knows, you can repay [because he knows you are with CDC]” 
(KP10)—means here more than just a bus ticket; here again, trial participation 
is about remaining connected, to escape geographical and often social isolation, 
and to live.
Being cared for
Striking in the women’s accounts was the lack of social networks and help 
that they could rely upon in times of need: vain attempts to secure funding for 
medical bills from husbands or relatives, and narratives of sick husbands unable 
to contribute—“it was at night and my husband refused to give out money so 
that I go to hospital so what could I do, I just gave birth” (KP9)—and not least 
stories about lack of trust between the women and husbands, relatives and 
neighbours, whom they hid their HIV status from. While some participants 
lived in supportive marriage and kin relationships, many others gave a picture 
of a lonely struggle for their own, and their children’s, survival, where study 
participation provided vital associations: “if I had not joined [the study], the way 
I later became sick, nobody would have treated me. I would have stayed in the 
house until I was yellow and there was nobody there to take me to the hospital” 
(KP8). 
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Under conditions of isolation (economically, and in kinship and gender 
terms, compounded by HIV status and stigma) it is not surprising that the 
women described their participation in an HIV research project in extremely 
positive terms: “they really care about the children. These [study] children 
of theirs, they really liked them’ (KP4); “they were happy people, they loved 
people, they loved us so much” (KP21); “They were taking good care of us. [...] 
transportation, [...] food, tea when you are hungry, there were nice to us” (KP6). 
Money, conviviality and attachment were intertwined: “like, sometimes I left 
my house before taking breakfast, so when they gave [breakfast] I say it is a 
good place because they consider others. Sometimes I could use my transport 
to come from home, and they gave it back to me; I said it is a good place, these 
people are really there to help me and I was happy with them” (KP1). 
The experience of caring personal relations was also underlined by the 
prevailing idiom of kin- and friendship (‘our baby’, ‘my sister’ etc.); and the 
boundary between reimbursements and gifts was further blurred by the fact 
that staﬀ members regularly extended the oﬃcial reimbursements with small 
personal gifts of money or in kind. Thus, most follow-up staﬀ who visited 
participants in their homes reported that they occasionally had given mothers 
small sums of money to buy food for their children, or brought them used 
clothes or ﬂour. ‘Being with’ a study created a collective—if temporary, unstable, 
fragmented—out of mutual claims and responsibilities, as well as aﬀect.
Material transfers came along with less tangible experiences of positive staﬀ 
attitudes and new relations: “they gave me ... encouragement, they are talking 
to you ...they don’t just talk to you like that” (KP15); “I was getting diﬀerent 
teachings [...that] make your heart strong: my husband had left me then, but 
I said that we are many, I am not alone.” (KP17). In particular, many mothers 
praised the knowledge they had gained—“knowledge on how I will continue 
living in good health, what I can do when I have a baby, the health of the child...” 
(KP9)—“a way of reasoning how one can live, with HIV” (KP12); “exposure”, 
as some of them called it, to new ways of thinking and living, enforced by a 
sense of encouragement and of being cared for, being included into a larger 
collective. All women wished for greater continuity in the relations with the 
research project, and expressed regret that ‘their’ trial had ended, and said that 
they would be happy to join another research project. They summarised these 
experiences in terms of relief, if only temporarily, from the burden of everyday 
survival: “I saw a lot of lightness [due to the fact that I am cared for]” (KP18); 
“They really set me free” (KP8).11 
11 | When, during a dissemination meeting that fed back trial results to the women, our 
own anthropological study was mentioned, almost all women were keen to join this new 
‘project’, even though it fell short of some expectations.
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This does not mean that everything was perfect. While most mothers 
appreciated the good healthcare, some were unhappy with how they were 
treated. Among the many who were proud that they had prevented their children 
from being HIV positive were others who had lost their children or had to cope 
with HIV positive babies. Some disagreed with particular staﬀ members, and 
about 50 women out of 500 left the trial because of misgivings, or because they 
did not see the point. Twelve women had died of AIDS during the trial either 
because they had been recruited in an advanced stage, or because they could not 
adhere to treatment. Almost all remained desperately poor after the trial and 
continued to struggle for their daily needs and for health care from insuﬃcient 
public institutions. What these quotes do suggest, however, is that material 
transfers, knowledge, conviviality, relatedness and belonging were intertwined 
in their experience. Economy and epistemology on the one hand, and morality 
and sociality on the other, were here not separate, even antagonistic domains, 
but mutually dependent and reinforcing each other. ‘Being with’ the study 
and the institution conducting it—‘being with CDC or KEMRI’, as people in 
Kisumu often say about trial participants as well as staﬀ—implies a broad sense 
of attachment. Even if this sort of belonging may not always be achieved or 
lasting, it appears that people who participate in trials seek a broader sense of 
association, beyond attaining immediate personal material fulﬁlment of needs. 
Material value, everyday needs, the desire for knowledge, trust and care, are 
mixed in trial participation in ways that make the liberal idea of individual 
autonomy and voluntariness questionable. Instead, monetary transactions and 
other transfers of material value are experienced as part of wider connections 
and collectives, larger possibilities and hopes. 
THE FAILURE OF THE GIF T?
A misnomer
Trials transfer value, including money, to participants; this value transfer is 
appreciated by recipients, and recognised by everybody involved; and yet it is 
excluded from the public space of the trial. It is, in the words of more than 
one of the researchers and staﬀ we spoke to, an ‘open secret’. This is morally 
and politically problematic. It can seem dishonest on a personal level, and may 
inhibit open debate, preventing questions of value and justice from being raised, 
and from becoming part of public debate about public health.12 As it stands, 
12 | One space in which such negotiations could have occurred were the ‘community 
advisory boards’ (CAB) that were set up by the HIV research group with distinguished 
‘community representatives’, and which served to facilitate ‘community engagements’, 
“WE ARE NOT PAID—THEY JUST GIVE US” 217
TR looks like a compensation for trial participants’ value-creating eﬀorts, which 
is set more or less arbitrarily by the trial management—analogous to a wage 
determined by the owner of the production process at will. 
Given the fact that everybody involved seems to have accepted that value 
is transferred in TR it would seem appropriate to abandon this performance 
of valuelessness. There isn’t much point to calling payments ‘transport 
reimbursement’ any more. But then, how ought one instead understand the 
transfers of value in clinical trials, epitomised by ‘transport reimbursement’, 
instead of concealing them. This ‘ought’ is not only a matter of representation—
how does one correctly represent the reality of value transfers—but at least as 
much a problem of deontology—how should one speak about the value of public 
health research, if one takes seriously the women’s biopolitical longing to be 
part of the trial, and aims to contribute to public (just, equitable) health in a 
healthy public sphere?13
Gift or commodit y?
The centrality of value in clinical trials stands in contrast to earlier bioethicists’ 
insistence that considerations of value and proﬁt—any nexus between trial 
participation and the fulﬁlment of needs—is antithetical to ethical research 
participant recruitment, and the negotiations of potential problems. However, during 
the years of this fieldwork the only occasions when transport reimbursement was 
discussed by the advisory board was in relation to the board members‘ own transport 
reimbursement, which eventually was set at a higher rate than that of research 
participants, presumably somehow related to the higher income of these employed or 
professional advisers. These dif ferent transport reimbursement rates again underline 
that something other than reimbursement is at play, in this case the dif ferent value 
of people, while the absence of other negotiations of reimbursement from community 
advisory board deliberations demonstrate the non-public nature of the reimbursement 
problem (and might raise the question whether the advisory board represents the 
interests of participants or of the research organisation).
13 | In a recent, methodologically very dif ferent, economic study carried out among 
Zambian HIV volunteers, experiments showed similarly, that money was at best part 
of social engagements and not the prime driver of voluntary health work (Ashraf et al. 
2011). Monetary incentives were here less efficient to provide motivation than ‘social’ 
rewards and recognition. While the authors explained this—limited by their rational 
actor paradigm—as pointing to ‘intrinsic motivation’ and ‘social comparison’ (rather 
than mere financial rewards) as prime drivers of action, they also note in an aside that 
the ‘reputable organization’ for whom the volunteers worked, might have influenced 
their willingness to contribute. From our perspective, this dimension of belonging to a 
larger whole would deserve greater weight.
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practice (see e.g. Titmuss 1970). This dissociation of ethical medicine from 
its political-economic context has been debated among progressive academic 
bioethicists for a while, most notably in reﬂections on ‘beneﬁt sharing’ around 
medical research (see e.g. Hayden 2007). Yet, in the Kenyan context, ethics review 
boards as well as scientists and institutions take as yet little notice of these on-
going discussions (see discussion in Lairumbi et al. 2011); and in practice they 
remain focused on protecting individual autonomy and voluntariness, which 
they see threatened by implications of need and interest. Ethics appears here 
as antithetical to economics. To remain ethical, material transfers attendant on 
bodily participation in research must conform to a speciﬁc idea of the gift—what 
anthropologists have referred to as the hypothetical concept of the ‘free gift’, a 
‘gift for nothing’, valueless, non-calculating, pure, and without expectation of 
return. Such gift should have no ties attached, not to other people, not across 
time, nor to one’s bodily needs and desires. 
From the observations about TR, above, one could then be led to conclude 
that this gift has simply failed as foundation for ethical medical science. Indeed, 
it seems futile to deny the omnipresence of value and calculation throughout 
human subject engagements with trials. If the gift has failed, its supposed 
opposite, the commodity rears its head. If people don’t deal with research in 
terms of gifts, well, then transactions are probably commoditised—that is they 
should be recognised as exchanges of value in diﬀerent currencies, including 
bodily substance, risk, time and money. This is a logical move, which some 
ethicists propose in an eﬀort to realign medical ethics and a particular economic 
notion of freedom. The crudest conclusion from this shift would be to consider 
research participants’ bodily materials as commodities—selling blood samples, 
organs etc.—but this conﬂicts with the near universal idea of the inalienability 
of the body. 
Instead, one could move to consider participation in trials as free 
‘labour’ (which can be bought and sold), and transactions of value, such as 
‘reimbursement’, as payments or wages. In recent literature this idea of ‘clinical 
labour’ (Cooper 2008) comes in two diﬀerent versions. One, proposed by some 
bioethicists, is economically liberal, aligning clinical labour with other unskilled 
labour in economically poor, low-wage settings, at a ﬁxed low rate—talking 
about the ‘price of a research subject’ (Dickert/Grady 1999)—accepting the 
commercialisation of research and the place of unskilled labour in late capitalism 
as givens. Trial participants are here, like labourers, free to choose selling their 
time and bodily substance. The second one, developed by anthropologists and 
sociologists of medical research, comes to a similar conclusion out of broadly 
Marxist reasoning. By critiquing the misrepresentations that the concept of 
the free gift produces, and replacing them with a materialist understanding, 
the hope is that the correct recognition of ‘clinical labour’ would unleash 
social transformation analogous to older labour movements. The former 
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proposition wants to adjust norms to the economic status quo, while the latter 
proposes, within a progressive deontology, to ﬁnd origins of political-economic 
transformation in the given material reality. While the political intentions of 
both arguments are somewhat diﬀerent, both seem to accept that the gift has 
failed, and the market—variously understood as invisible hand, or as generative 
of transformative contradictions—has taken over. 
If matters are discussed, and resolved, within this frame, the linkage between 
bodily participation in public health research and similar medical practices and 
the older biopolitical collective exempliﬁed by the developmental nation-state 
fades from view; the market appears as the only possibility in a post-governmental 
age. In the remainder of the chapter I consider the possibilities and limitations 
of this move in view of the evidence, above as well as in the literature on ‘trial 
communities’, that clinical trials in Africa (and similar settings) continue to 
engender associations and visions of collectives, against the backdrop of the 
relative weakness of the older nation-state forms of collectivity. I will conclude 
by considering what the gift, which according to anthropologists never was free, 
may still have to oﬀer to our rendering of medical research and public health.
Emergent labour markets?
The notion of ‘clinical labour’, noted above, does open some political possibilities. 
In some situations, participants’ bargaining power could allow for negotiations 
about the fair remuneration for their eﬀorts. One of these situations is in the 
middle of long term trials, when each participant carries the value of the previous 
investment into examinations, treatments and other procedures; at this stage, 
participants are, as trial staﬀ are the ﬁrst to acknowledge, ‘too valuable to lose’, 
and trial managers and researchers invest considerable additional funds into 
maintaining participants or ﬁnding them and bringing them to the clinic (yet, 
participants seem to rarely notice the relative power they hold at this point, partly 
because they have started worrying about the end-of-the-trial). Another situation 
of potential bargaining power is when a research organisation has established 
a long term research site with high investment of capital, infrastructure and 
training; in such trial sites, which are increasingly common all over Africa, 
negotiations with (potential) participants are increasingly high on the agenda—
often under the heading of ‘community engagement’ and ‘public engagement’ 
(see Molyneux et al. 2005). Finally, participants hold bargaining power where 
diﬀerent research groups or projects operate in the same area and compete for 
participants. Here we see some form of incipient struggle, in which we can 
discern the shapes of an emergent clinical labour market.
If, within one area, diﬀerent research groups oﬀer diﬀerent TR rates to 
the same potential trial population, this is quickly picked up by potential 
participants and discussed in terms of payment. Competition becomes 
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particularly sharp when diﬀerent trials are looking for participants with speciﬁc, 
rarer conditions or particular risks, in the same population. This situation is less 
uncommon than one would think, partly because transnational clinical trials are 
increasingly concentrated in large-scale, long-term research sites with favourable 
epidemiological conditions and global standard laboratories and facilities, and 
partly because scientiﬁc and policy developments, as well as drug market trends, 
can lead to waves of certain kinds of studies at a given time. If, for example, in 
HIV research and intervention, male circumcision is en vogue, young men have 
an edge; if HIV resistance genomics are hot, prostitutes in cities with state of the 
art laboratories are needed; and if drugs for pre-exposure prophylaxis (PREP) 
are to be tested, HIV negative members of ‘high risk groups’ such as prostitutes, 
youths or widows are needed; for such studies, HIV discordant couples, in 
which one partner is positive and one not, and in which both infective and 
uninfected partner can be enrolled in the same trial (giving either the positive 
or the negative part antiretroviral treatment to prevent transmission between 
them) are in particularly high demand.
The market analogy of these situations is recognised by trial managers 
who may express concern with the diﬀerences between diﬀerent research 
collaborations’ TR payments and the competitive eﬀects on recruitment and trial 
success. As managers, they are constrained both by institutional agreements 
and study protocols, and by budgets, and ﬁnd themselves thus squeezed 
between the need of recruiting numbers within a limited time, and the need to 
cap production costs—like any manager in moments of labour scarcity. In such 
situations, participants might enter into actions that bear analogy to incipient 
labour struggles. One of the more rudimentary forms of contestation is ‘double 
enrolment’ in more than one trial at the same time. This poses a scientiﬁc 
problem as it may aﬀect a trial’s validity, and a grave medical and ethical concern, 
as it might aﬀect the health of the participant, especially where pharmaceuticals 
and invasive procedures are involved. Another form of contestation can be 
found in rumours about the ‘exploitation’ of research subjects and the alleged 
proﬁts of the researchers—the so called ‘guinea pig’ rumours, which can express 
discontent and make claims for better remuneration (Geissler/Pool 2006; 
Leach/Fairhead 2007; Graboyes 2010; see White 2000). Thus, in 2004, a main 
national broadsheet carried large articles in which inhabitants of Kemri/CDC’s 
demographic surveillance system accused the institution of major abuses; CDC 
responded, exposing the cited witnesses as disgruntled ex-employees, and by 
setting up a dedicated and well-funded “community engagement” section, with 
the “responsibility ... to generate community support and acceptance for KEMRI/
CDC activities and to mobilize the community for informed participation”. If 
local resistance and claims were put forward in more organised forms, demands 
for compensation, or just higher TR, might be pushed forward by local groups 
like ‘community based organisations’, which often play an important role in 
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trial recruitment itself, or even by local administrators and chiefs, on behalf of 
their constituency. Such situations may oﬀer opportunities to mobilise critical 
research subject advocacy in Africa, which so far have often failed because they 
did not account for African participants’ fundamental desire to be part, through 
trials, of larger regimes of reliability and care.
In spite of these incipient political possibilities, so far research institutions 
and groups respond eﬀectively—though mostly unwittingly—to preclude the 
possibility of such challenges. One important strategy is, not unlike missionary 
societies of the past, to stake out territorial claims, which are more or less 
informally negotiated with and acknowledged by diﬀerent groups. Thus, in 
western Kenya, one large zone covering several districts is the principal area 
of KEMRI/CDC research (as well as, until recently, KEMRI/CDC managed, 
GAP funded HGIV care and treatment), a neighbouring district is covered, in 
terms of research and HIV care, by the US Department of Defence, beside this 
area is (with a slight, not unproblematic overlap) a zone ‘run’ by AMPATH, the 
‘Academic Model Providing Access to Healthcare’, a Kenyan bridgehead of major 
US Medical Schools combining research and care provision, and parts of Kisumu 
city by FACES, ‘Family AIDS Care and Education Services’, a similar outﬁt 
initiated by another main US medical school running numerous collaborative 
trials etc. This territorial organisation ensures relatively uncomplicated 
recruitment in one’s given study area—although for rare participant types like 
discordant couples, these might have to travel some distance to attend a particular 
trial—and avoids competitive participant claims. Also, the massive investments 
made during the past decade by the leading transnational research groups, 
universities and funders in local infrastructure, allow groups to lay claim to 
areas and their populations and preclude competition. If a territorial agreement 
cannot be reached, the very diﬀerent resources and power of research groups or 
organisations can lead to eﬀective struggles over territories, and weaker groups 
tend to withdraw from areas worked on by stronger ones.
An important mechanism in this context is demographic surveillance data 
collection, i.e. establishing longitudinal databases of the population in particular 
areas as well as their morbidity, which constitutes the backbone of randomised 
controlled trials in many parts of Africa. Such demographic surveillance 
systems, which come at very high cost and greatly enhance the value of a study 
population, constitute a novel form of governance over a speciﬁc territory 
(usually in the range of 100-300.000 inhabitants, in some cases much more) 
which is much more long-term than the usual clinical trial; as such they tend to 
prevent incursions by non-collaborating research groups, and thus competition 
for participants. While demographic surveillance areas indubitably stake a 
claim in an area, they also provide a form of governance and attendant forms of 
citizenship, which can be utilised both for improved health care provision, as is 
the case in many surveillance areas, and as a framework for wider negotiations 
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about clinical trials, their beneﬁts, and other health care related matters. They are 
thus both a potential mechanism of control and of representation, of discipline 
and democracy.
If competition cannot be avoided and diﬀerent groups work on similar 
issues in one area, double enrolment can be prevented using Photo ID 
cards and ﬁngerprint readers, and sharing the attendant person-codes and 
data between diﬀerent projects and research organisations. This strategy is 
increasingly used by clinical trials management in areas without reliable person 
registration and documents, and high concentration of research. And ﬁnally, 
if diﬀerent clinical trials by several groups have to share the same population, 
the inevitable competitive instincts between groups and their scientiﬁc leaders 
must be overcome and agreement reached over TR rates and the level of other 
participant beneﬁts.14 
Freedom?
As these examples show, the political promise of reframing research 
participation as labour is still limited given the unequal distribution of power, 
and the unlimited pool of (bare-)life labour. More important doubts also arise on 
a more analytical level. The older bioethicists who insist on participation being 
a free gift, and those who advocate the liberation of ‘clinical labour’ could be 
opposed (and pose at times) as ‘idealist’ and ‘materialist’. However they share 
certain premises regarding the nature of money and monetary exchange.
First, they seem to agree that moral and economic considerations belong to 
separate spheres and should not be conﬂated, each of them giving, respectively, 
priority to morality or political economy. Promiscuity between the two is a 
threat, much as in Marx’ understanding as acid that dissolves the social. Money 
materialises the abstract, amoral, calculating quality of economic rationality 
that must be kept away from moral reasoning, lest sociality will suﬀer. This 
understanding of money as amoral, even immoral, and anti-social, does not 
seem to be as obvious to the women quoted above, who appreciated precisely 
the moral value of monetary support as much as the material manifestations of 
care. The distinction between money and morality has for long been analysed 
14 | In this case, if groups actually negotiate to cap reimbursements and benefits at 
one level in order to curb competition, TR is treated almost openly like labour-wage 
within a labour market, running very much against the formal denial of TR being a 
payment. This paradox is possible, because the two processes happen on the dif ferent, 
disjointed levels of the protocol and its GCP commitments, and of trial managers and 
local implementers; and because the two operations are separated, in the everyday 
of trial planning and operations, by the veil of discursive rigour, denial and ironic 
detachment.
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as a crude simpliﬁcation by social anthropologists who showed that monetary 
exchanges and moral action are commonly intertwined, and that the neat 
separation between morality and economy may indeed be part of a particularly 
cultural formation, or even of an ideology of capitalism, while people all over the 
world, including those in core capitalist institutions, tend to mix and connect 
economic and moral domains (see e.g. Shipton 1989; Parry/Bloch 1989; Maurer 
2006; see also Mauss 1923). In other words, the common-sense association of 
money with individuation and rational calculus, which continues to underlie 
much medical ethical discourse, might not be helpful to understand the 
workings of value, and values, in a clinical trial.15 
The notion of money as abstract and individuating is linked to another 
premise shared by advocates of purist bioethics and of clinical labour alike: 
the idea of freedom and autonomy as basis of good science. For both, the gift 
is free, that is an (individual) gesture without calculus, value and expectation 
of direct return, performed by free, individual actors out of individual moral 
(or spiritual) motivation. This idea of gifting is in their vision opposed to an 
alternative vision of individual action as commodity exchange, premised upon 
self-interest, calculation and the maximisation of pleasure or utility. Liberty and 
autonomy are here the central nodes around which both the free gift, and free 
labour are constructed. 
What is absent from both these renderings of value transactions is the 
notion of a collective—a ‘social’—be it as an existing reality that facilitates and 
underwrites value transfers, in the way in which the nation-state did in mid-20th 
century ideas about voluntary blood donation (e.g. Titmuss 1970), or as project 
entailed by these transfers, a future evoked by transacting value, such as in the 
communities engendered by ‘beneﬁt sharing’ in relation to bioprospecting and 
intellectual property (see Hayden 2007). The possibility of value transactions, 
not as individual acts but as produced by and productive of collective forms does 
not occur either in the imaginary of free gifting, or in the alternative proposition 
of free labour. It is assumed that the act of giving and receiving material value 
is a momentary engagement between individuals, existing in the present. These 
15 | In the scientific context examined here, a related common assumption about 
money deserves mention. By engendering an interest in personal profit, money might 
endanger not only moral reasoning, but also the (supposedly amoral) validity of 
scientific knowledge which, in theory, arises from impartial investigation premised 
upon universal social values. Economy and epistemology are here opposites, just like 
morality and economy. While this argument deserves consideration where funding for 
medical research and the commodification of its results are concerned, this opposition 
does not seem to hold for the women above, for whom ‘being with’ the trial produced 
simultaneously knowledge of medical facts as well as health care possibilities, and 
opportunities for modest material gain.
P. WENZEL GEISSLER224
assumptions about the (a)sociality and (a)temporality of clinical trial transactions 
reﬂect only one, narrow understanding of the gift, which may be symptomatic 
of the current historical, political-economic condition, which some sociologists 
also described as the ‘death of the social’ (Rose 1996). 
While it may be practically advisable to acknowledge the vital value transacted 
in TR (and thus to get rid of the misnomer of ‘transport reimbursement’), this 
does not lead to the replacement of the pure gift with a pure commodity or free 
labour. By way of conclusion, I want to argue in favour of retaining, somewhat 
doggedly, the notion of the gift to science.
END: GIF T AS COLLECTIVE
When I propose that we hold on to the notion of the gift to designate trial value 
transfers, it is not in the sense of a pure, free gift, but as a gift in a classic 
anthropological sense (supported by the trial participants’ experiences detailed 
above). Gifts imply, ﬁrstly, social relationships, attachments, and the collectives 
that arise from such associations; and secondly, they are deployed over time 
involving memories of past actions as much as anticipations of futures. The gift 
understood as such is thus a pointer towards futures collectives and possibilities, 
as early anthropologists had argued and as has been reiterated with diﬀerent 
emphasis for more than a century of anthropological writing (e.g. Malinowski 
1922; Mauss 1923; see e.g. Strathern 1988).
In a completely diﬀerent social and historical context from that of classic 
ethnographic accounts, but somewhat closer to our clinical trial site, the link 
between gifting and collective forms was explored by Richard Titmuss in his 
work on blood donation in mid-twentieth century Britain (Titmuss 1971, in 
Oakely and Barker 2004)). In Titmuss’ version, the collective in question is the 
nation-state, and, he argues, it is because this collective is already in place that 
people are able to give ‘gifts to strangers’ (1970). What Titmuss’ analysis is less 
interested in, is that gift-value transfers also contribute to bringing collectives 
into being. The post-war British National Health Service, Titmuss’ prime subject 
of analysis, was not only premised upon the nation but also contributed to the 
creation of the speciﬁc mid-twentieth-century British nationhood. For Titmuss, 
the nation-state in its post second world war welfare version was a quasi-natural 
frame of reference and the question of how collectives such as this come into 
being was of less interest than what they can make one do.16 By contrast, if we 
think about practices such as blood donation—or transnational clinical trials—
16 | While the foundation of the NHS was premised upon a nation state that had just 
emerged solidified from the collective effor t of the World War, the question of how, in 
turn, health services can help making the nation was a more obvious issue in Titmuss 
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today, the nation-state no longer provides such an obvious framing. Indeed, as 
Cecilia Busby has warned us, the nostalgic evocation of past collectives such as 
‘the nation’ can be problematic and indeed dangerous in a situation where the 
nation-state has decayed or where it no longer pursues public wellbeing (2006). 
Such, we might argue, is the case in some contemporary African nations.17
If I suggest here that we recognise the ability of gifting to create collectives 
and open futures, I do not want to evoke ‘traditional’ cultural collectives of the 
Levy-Bruhl’ian kind (pace certain African bioethicists ‘Ubuntu’-inclinations); 
neither do I believe that we can ‘return’ post-neoliberal Kenya to Titmuss’ 
(and Keynes’) 1948 welfare Britain. But at the very least we should expand—
maybe inspired by these older imaginaries—our ethnographic sensitivities 
to the possible collectives and aspirations that are implied and evoked when 
trial participants choose to give their time and bodily substance, and to accept 
material transfers of value, including money. 
Citzenship as experiment
Partly in response to the less stable and obvious nature of government and 
national collective today, compared to Titmuss’ times, the past decade has seen 
an abundance of fruitful anthropological explorations of increasingly manifold, 
ﬂuid and fragmented ‘citizenship(s)’, including, importantly ‘biological 
citizenship’ (Rose/Novas 2005). The latter concept, and its more comprehensive 
predecessor ‘biosociality’ (Rabinow 1996), would seem particularly relevant 
here (see especially Biehl 2004; Nguyen 2004). The social ties described above 
could, derived from this literature, be described as ‘experimental citizenship’. 
Such terms would reﬂect some of the participating women’s claims and desires: 
the material transfers provided by the trial substitute in part for the welfare and 
health care they would be entitled to as national citizens, and in turn most of 
them struggle to be ‘good citizens’ of the trial and of KEMRI/CDC. ‘Experimental 
citizenship’ would also reﬂect the peculiar nature of this kind of association: it is 
citizenship on time, on trial, more a search for citizenship, than a comprehensive 
and lasting attachment as national citizenship would claim to be. 
On the other hand, describing the tentative associations produced within 
the trial as (yet) another form of ‘citizenship’ risks devaluing the larger promise 
held out by the older, more comprehensive political project, conceived in 
enlightenment readings of an even older civitas. The inﬂationary use of multiple 
citizenshipS makes it diﬃcult to measure the shortcomings of emergent and 
effor ts to help shaping the health services of the newly independent nation Tanzania 
(see Titmuss 1964).
17 | Busby reminds us that the relationship between imaginaries of association and 
political economic realities needs to be continually assessed (2006). 
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fragile forms of association that arise, in part, in response to the collapse 
of nation-state citizenship; the latter seems now just like one of many of its 
kind, rather than a universal standard and aspiration. Thus, although trial 
participation might entail a search for a lost citizenship, and although it indeed 
is an experimental social formation, the multiplication of citizenships is marred 
by the same problem as the anthropological proliferation of ‘modernities’ in 
the 1990s: that of discounting people’s aspirations for a more encompassing, 
universalist and enduring form of societal association (see Ferguson 2006). 
The women quoted in this essay evoke the ‘hospitality’ and conviviality 
of trial relations, they describe trust and care, and they make reference to the 
larger institutions of scientiﬁc knowledge of health care and of government 
that they imagine behind their clinical trial. These allusions to ‘being with’ 
something larger than individual and local do not map onto one another, nor 
add up to one coherent whole. Some are limited to the trial in question and 
its caring staﬀ; others refer to the Kenyan and US government institutions 
behind it; others again evoke the certiﬁed standards of drugs and diagnostics 
sourced from Europe or the US; and all of them are aware of the ephemeral 
temporality of any of these associations, and yet, they yearn for a stability (that 
in turn is referenced in memories and remains of past national projects). 
These associations cannot match the high-modern ‘imagined community’ of 
the nation-state. But although these imagined and experienced collectives are 
limited and temporary, they reveal the Kenyan trial participants’ longing for 
biopolitical inclusion. In the absence of eﬀective care or control, leave alone 
biomedical discipline, even fragments of larger wholes are objects of desire: the 
chip card for trial participants, the GIS based surveillance, the ﬁnger print scan, 
even the regular blood specimen collection, become not threatening targets of 
potential anti-biopolitical resistance, but signify towards imaginary—sometimes 
remembered—modes of inclusion and citizenship.
Similar observations to those above were made by other ethnographers who 
attended to the experience of African participants in transnational public health 
research and found that they pursued long-term relations and new kinds of 
belonging in their engagements with clinical trials, rather than seeking mere 
material beneﬁts or means of survival under conditions of deprivation (and 
far from resisting the threat of biopolitical domination) (see especially Leach/
Fairhead 2007; Molyneux et al. 2005; Geissler et al. 2007). This does not mean 
that a Kenyan woman gifting bodily specimens and accepting reimbursements 
necessarily has a clear picture of the collectives and aﬃliations she aims to attach 
herself to, and in this regard her situation may be diﬀerent from mid-20th century 
nation-state citizens. Maybe the collectives that she seeks to associate herself to 
do not yet exist in a speciﬁc form. It is through her attachments that she pursues 
them and that they gradually, and partially, take shape. As ethnographers—as 
well as scientists in public health, I would argue—we should attend to this 
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search for ‘transport’, mentioned earlier in this chapter, for movement and 
transformation—of knowledge and of the world that is made known—beyond 
the existing conditions of life and of economic, political and social deprivation.
In Africa after the demise of the monolithic biopolitical nation-state, 
our primary challenge then may not be to discern and critique (or delineate 
resistance to) the classic biopolitical regimes of surveillance and discipline—
which have become almost extinct species, conﬁned to the reservations of 
demographic surveillance systems and HIV treatment programmes—but to 
attend to the longing and nostalgia that these older, once threatening orders 
evoke today. The shadow, not of the dark, imposing underside of modernity as 
in 1970s antimodernism, but the rather more faint shadow of a distant modern 
constellation, which from the vantage point of contemporary African ex-citizens 
of biopolitical nationhood, appears again as an utopia.18 
18 | In terms of concrete responses to this situation, then, the proposition by de 
Cernival to extend health care in clinical trials to everybody, within and outside the trial, 
points towards a political debate about the collectivising aims of public health research 
(de Cernival 2008). Although theoretically closely linked to the liberal ‘clinical labour’ 
proposition, above, this seems to me a politically more promising route.
